Latest data

Independent journalism on peptide research, trials, and regulation. We do not sell peptides. Our editorial standards

Top StoryResearch

Cagrilintide Maridebart cafraglutide Abaloparatide Teriparatide Retatrutide Setmelanotide Orforglipron Humanin

This Week in Peptide Research: GIP Receptor Debate, Bone-Building Peptides, and New Safety Signals

A week of new PubMed literature brought dueling papers on activating versus blocking the GIP receptor for weight loss, fresh evidence on bone-building peptides, safety analyses touching retatrutide and weight-loss drugs generally, and a formal regulatory profile of orforglipron following its April 2026 approval.

Read full story

Is it legal? Check any peptide

Legal status by country, sport-legality, and cited evidence for all 56 tracked peptides

Full regulatory matrix

Are peptides legal in the US?FDA status of every tracked peptide Are peptides legal in Australia?TGA status of every tracked peptide Legal in the European Union?EMA status of every tracked peptide Which peptides are banned in sport?WADA status of every tracked peptide

Latest News

All news

News
BMJ Study Links GLP-1 Receptor Agonists to Higher Hair Loss Risk in Type 2 Diabetes
A target trial emulation study of more than 50,000 Penn Medicine patients, published in The BMJ on July 22, 2026, found GLP-1 receptor agonist users had a 37 to 68 percent higher relative risk of clinically recorded hair loss than patients on two other diabetes drug classes, though absolute risk remained low.
Semaglutide (Approved)Tirzepatide (Approved)
Peptide Science Daily StaffJul 23, 20265 min
Research
Lilly Posts Phase 3 Results for Oral Orforglipron in Japan-Only ATTAIN-J Obesity Trial
Results filed to ClinicalTrials.gov on July 20, 2026 show body weight reductions of up to 8.7 percent at 72 weeks in 238 Japanese adults with obesity, alongside higher rates of gastrointestinal side effects and one death in the highest-dose group.
Orforglipron (Approved)
Peptide Science Daily StaffJul 20, 20265 min
News
European Commission Approves Oral Wegovy Pill for Weight Management in the EU
The July 15, 2026 decision authorizes a once-daily 25 mg semaglutide tablet as the first oral GLP-1 receptor agonist for weight management across the European Union, following a CHMP recommendation adopted in May.
Semaglutide (Approved)
Peptide Science Daily StaffJul 18, 20264 min
Research
Zalfermin Plus Semaglutide Misses Its Primary Endpoint in Phase 2 Liver Fibrosis Trial
In a 698-person trial spanning fibrosis stages F2 through compensated cirrhosis, the Novo Nordisk combination did not significantly beat placebo, though semaglutide alone showed a nominal signal, according to results published in The Lancet Gastroenterology & Hepatology on July 15, 2026.
Semaglutide (Approved)Cagrilintide (Investigational)
Peptide Science Daily StaffJul 16, 20266 min

Advertise with usReach a focused audience of peptide researchers, clinicians, and industry readers.Rates & availability

Research
ACHIEVE-2: Oral Orforglipron Outperformed Dapagliflozin on Blood Sugar in Phase 3 Diabetes Trial, Lancet Reports
In a 40-week trial funded by Eli Lilly, all three tested doses of the oral GLP-1 pill met the study's non-inferiority bar against a standard SGLT2 inhibitor and produced larger average HbA1c reductions, alongside more gastrointestinal side effects and discontinuations.
Orforglipron (Approved)
Peptide Science Daily StaffJul 12, 20266 min
Research
The TRANSCEND Trial: Setmelanotide Reduced BMI in Acquired Hypothalamic Obesity, NEJM Data Show
A phase 3 trial published in the New England Journal of Medicine found the approved MC4R agonist lowered BMI by 16.5% over 52 weeks in patients with obesity caused by hypothalamic tumors or injury, versus a 3.3% increase on placebo.
Setmelanotide (Approved)
Peptide Science Daily StaffJul 11, 20265 min
Research
BMJ Network Meta-Analysis Compares 19 Obesity Drugs on Weight Loss, Heart Risk, and Side Effects
A systematic review of 262 trials and nearly 100,000 patients puts tirzepatide, semaglutide, CagriSema, orforglipron, and other peptide-based therapies side by side, and finds that larger weight loss usually comes with larger trade-offs.
Tirzepatide (Approved)Semaglutide (Approved)Cagrilintide (Investigational)Orforglipron (Approved)Retatrutide (Investigational)Mazdutide (Approved)
Peptide Science Daily StaffJul 10, 20267 min
News
FDA Advisory Committee to Weigh Compounding of BPC-157 and Other Research Peptides
The Pharmacy Compounding Advisory Committee is scheduled to review seven peptides for the Section 503A bulk drug substances list on July 23-24, part of a broader reconsideration of substances the agency flagged in 2023.
BPC-157 (Restricted / Rx-only)TB-500 (Prohibited)KPV (Investigational)MOTS-c (Prohibited)
Peptide Science Daily StaffJul 1, 20265 min
News
FDA Scientists Question Evidence for Peptides Backed by RFK Jr. Ahead of Advisory Panel
Career reviewers at the agency posted documents finding little human evidence for BPC-157, TB-500 and five other peptides, setting up a clash with Health Secretary Robert F. Kennedy Jr., who has pushed to widen access before the July 23-24 advisory meeting.
BPC-157 (Restricted / Rx-only)TB-500 (Prohibited)KPV (Investigational)MOTS-c (Prohibited)Semax (Investigational)Epithalon (Investigational)DSIP (Investigational)
Peptide Science Daily StaffJul 1, 20266 min
Research
Retatrutide Phase 2: A Triple-Agonist Peptide and 24% Average Weight Loss at 48 Weeks
A single investigational molecule engages three metabolic hormone receptors at once. Here is what the New England Journal of Medicine data actually showed, and what it does not.
Retatrutide (Investigational)
Peptide Science Daily StaffJul 1, 20266 min
News
Australia Becomes First Country to Schedule BPC-157 as Prescription-Only
A TGA decision added the experimental peptide BPC-157 to Schedule 4 of the Poisons Standard effective June 1, 2024, amid warnings about a growing market for unapproved peptide products.
BPC-157 (Restricted / Rx-only)
Peptide Science Daily StaffJun 27, 20264 min
Research
The SELECT Trial: Semaglutide Cut Major Cardiovascular Events by 20% in People Without Diabetes
A landmark outcomes study asked whether a GLP-1 peptide prevents heart attacks and strokes, not just weight. The 17,604-person answer reshaped how the class is viewed.
Semaglutide (Approved)
Peptide Science Daily StaffJun 24, 20266 min
News
Novo Nordisk Files CagriSema, a GLP-1/Amylin Combination, for FDA Review
The company submitted a New Drug Application on December 18, 2025 for the once-weekly injection combining semaglutide and the amylin analogue cagrilintide for chronic weight management.
CagriSema (Investigational)Cagrilintide (Investigational)Semaglutide (Approved)
Peptide Science Daily StaffJun 20, 20264 min
Research
SURMOUNT-1: How a Dual GIP/GLP-1 Peptide Delivered Up to Roughly 21% Weight Loss
The pivotal obesity trial for tirzepatide reset expectations for what a single injectable peptide could achieve. A look at the actual numbers, endpoints, and caveats.
Tirzepatide (Approved)
Peptide Science Daily StaffJun 17, 20266 min
News
FDA Grants Accelerated Approval to Wegovy for MASH With Liver Fibrosis
The August 15, 2025 decision made semaglutide 2.4 mg the first GLP-1 receptor agonist cleared to treat noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis.
Semaglutide (Approved)
Peptide Science Daily StaffJun 12, 20264 min
News
Lilly's Retatrutide Posts Up to 28% Weight Loss in First Phase 3 Obesity Readout
Topline results from TRIUMPH-1, the first pivotal trial of the investigational triple-hormone agonist, showed average weight reductions of roughly 19% to 28% across three doses over 80 weeks.
Retatrutide (Investigational)
Peptide Science Daily StaffMay 21, 20265 min

Live Trackers

Data aggregated from primary regulatory and trial sources

All trackers

Clinical Trials Tracker

3623Registered trials tracked

Registered interventional trials across GLP-1, tissue repair, anti-aging, and metabolic peptide categories.

Regulatory Status Tracker

56Compounds monitored

FDA, EMA, TGA, and Health Canada regulatory status for peptide therapeutics and research compounds.

Adverse Events Database

61,284FAERS reports · tracked compounds

Aggregated adverse event reports associated with peptide compounds from the FDA FAERS pharmacovigilance database.

Study of the Week

Research archive

Abstract molecular ribbon model of a metabolic peptide

New England Journal of Medicine

Semaglutide

The SELECT Trial: Semaglutide Cut Major Cardiovascular Events by 20% in People Without Diabetes

Coverage by Peptide Science Daily Staff, Editorial DeskJune 24, 2026

Study limitations: A secondary-prevention population (older adults with established cardiovascular disease, predominantly male and white); the results do not establish benefit in people without established heart disease. Not medical advice.

Read original paper

Explore Compounds

All compounds

Independent, citation-grounded reporting on peptide trials, regulatory decisions, and safety signals. No hype, no purchase prompts.

Weekly digest of peer-reviewed peptide research
Trial updates and recruiting notifications
Regulatory moves from FDA, EMA, TGA, and Health Canada

Independent publication. We do not sell or supply peptides. No spam. No purchase prompts. Unsubscribe at any time.

This Week in Peptide Research: GIP Receptor Debate, Bone-Building Peptides, and New Safety Signals

Is it legal? Check any peptide

Latest News

BMJ Study Links GLP-1 Receptor Agonists to Higher Hair Loss Risk in Type 2 Diabetes

Lilly Posts Phase 3 Results for Oral Orforglipron in Japan-Only ATTAIN-J Obesity Trial

European Commission Approves Oral Wegovy Pill for Weight Management in the EU

Zalfermin Plus Semaglutide Misses Its Primary Endpoint in Phase 2 Liver Fibrosis Trial

ACHIEVE-2: Oral Orforglipron Outperformed Dapagliflozin on Blood Sugar in Phase 3 Diabetes Trial, Lancet Reports

The TRANSCEND Trial: Setmelanotide Reduced BMI in Acquired Hypothalamic Obesity, NEJM Data Show

BMJ Network Meta-Analysis Compares 19 Obesity Drugs on Weight Loss, Heart Risk, and Side Effects

FDA Advisory Committee to Weigh Compounding of BPC-157 and Other Research Peptides

FDA Scientists Question Evidence for Peptides Backed by RFK Jr. Ahead of Advisory Panel

Retatrutide Phase 2: A Triple-Agonist Peptide and 24% Average Weight Loss at 48 Weeks

Australia Becomes First Country to Schedule BPC-157 as Prescription-Only

The SELECT Trial: Semaglutide Cut Major Cardiovascular Events by 20% in People Without Diabetes

Novo Nordisk Files CagriSema, a GLP-1/Amylin Combination, for FDA Review

SURMOUNT-1: How a Dual GIP/GLP-1 Peptide Delivered Up to Roughly 21% Weight Loss

FDA Grants Accelerated Approval to Wegovy for MASH With Liver Fibrosis

Lilly's Retatrutide Posts Up to 28% Weight Loss in First Phase 3 Obesity Readout

Live Trackers

Study of the Week

The SELECT Trial: Semaglutide Cut Major Cardiovascular Events by 20% in People Without Diabetes

Explore Compounds

BPC-157

Retatrutide

Semaglutide

Tirzepatide

TB-500

CJC-1295

Epithalon

GHK-Cu

BPC-157

Retatrutide

Semaglutide

Tirzepatide

TB-500

CJC-1295

Epithalon

GHK-Cu

The science briefing researchers actually read